Sonoma Pharmaceuticals, Inc. current report, 29 June 2011

Abrir documento

Business Context and Reporting Period

This Form 8-K was filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on June 29, 2011. The report details the entry into material definitive agreements regarding new debt financing and amendments to existing loan covenants.

Key Financial Metrics and Debt Structure

  • New Debt Facility: Entered into a Loan and Security Agreement with Venture Lending & Leasing VI, Inc. for up to $2,500,000.
  • Initial Drawdown: Borrowed $1,500,000 on July 1, 2011 (first tranche).
  • Interest Rates: Cash interest rate of 10%; effective interest rate of 13% including fees and warrant costs.
  • Repayment Terms:
    • First 9 months: Interest-only payments of $12,500 per month.
    • Subsequent 30 months: Principal and interest payments of $56,250 per month.
    • Final balloon payment: $116,505 due September 29, 2014.
  • Collateral: The loan is secured by the company's assets, including intellectual property.
  • Warrant Issuance: Issued a warrant for 226,325 shares at a strike price of $1.657 per share. Additional warrants may be issued if the second tranche is drawn.

Material Changes and Agreements

The filing reports two primary material changes:

  1. New Financing: Establishment of a new credit facility with Venture Lending & Leasing VI, Inc., allowing for a potential additional $1,000,000 draw upon meeting specific milestones.
  2. Amendment to Existing Debt: Amended the May 1, 2010 Loan Agreement with Venture Lending & Leasing V, Inc. (VLL5) to classify the liens securing the new VLL6 debt as "Permitted Liens" and to restate the definition of "collateral."

Outlook, Risks, and Contingencies

  • Warrant Put Feature: The lender holds a put option to sell the warrants back to the company for $937,500 (increasing to $1,250,000 if the full loan is drawn). This option becomes exercisable 60 days after a change in control, $20 million in new equity financing, or July 31, 2015.
  • Warrant Expiration: All warrants expire on November 30, 2018, and include a cashless exercise feature.
  • Forward-Looking Statements: The company notes that actual results may differ materially from expectations due to risks described in its Form 10-K.
  • Regulatory Compliance: The warrant issuance relied on Section 4(2) exemption from registration, offered only to accredited investors.

Investor Verification Checklist

  • Verify the company's ability to meet the milestones required to draw the second tranche of $1,000,000.
  • Review the impact of the 13% effective interest rate and monthly cash outflows on current liquidity.
  • Assess the potential dilution from the initial warrant (226,325 shares) and potential future warrants.
  • Confirm the status of the "Permitted Liens" amendment and its effect on the existing VLL5 loan covenants.
  • Monitor the put option trigger dates (July 31, 2015) and the company's cash position to cover the potential $937,500+ put exercise.